EyePoint Earnings Call Transcripts
Fiscal Year 2026
-
DURAVYU is advancing through four phase III trials for wet AMD and DME, with strong safety and efficacy data supporting non-inferiority to EYLEA and significant reduction in treatment burden. Top-line results for LUGANO are expected in August, and the company is well-funded through 2027.
-
Phase III trials for DME and wet AMD are progressing on schedule, with strong safety and efficacy signals and a unique mechanistic profile for DURAVYU. The company anticipates significant market share and expedited regulatory timelines, leveraging operational efficiencies and a differentiated product profile.
-
Two pivotal phase III wet AMD trials are fully enrolled, with LUGANO data expected mid-year and DME trials underway. DURAVYU aims for six-month dosing, strong safety, and broad market potential, with robust financials supporting programs into 2027.
-
DURAVYU, a sustained-release retinal therapy, is advancing through phase III trials for wet AMD and DME, with top-line data expected mid-year. The product's multi-mechanism action and six-month dosing aim to address unmet needs, supported by strong safety, robust financials, and a scalable manufacturing facility.
Fiscal Year 2025
-
DURAVYU advanced through pivotal Phase III trials in wet AMD and DME, supported by strong safety and efficacy data, robust cash reserves, and expanded commercial readiness. Top-line data for wet AMD is expected in mid-2026, with DME data in 2027.
-
Phase III trials for wet AMD are fully enrolled with data expected mid-2026, while DME trials will begin dosing in early 2025. Duravyu's multi-MOA sustained-release platform targets major unmet needs, aiming to reduce treatment burden and improve outcomes, supported by strong safety and robust funding.
-
Pivotal phase III trials in wet AMD are fully enrolled, with top-line results expected mid next year, while DME phase III trials will begin in Q1. The sustained-release therapy offers a novel multi-mechanism approach, showing strong safety and efficacy, and aims for a first-to-market advantage.
-
DURAVYU's phase III wet AMD trials are fully enrolled with top-line data expected mid-2026, and the DME program is set to begin dosing in Q1 2026. Q3 revenue declined year-over-year due to prior licensing, but a strong cash position supports operations into Q4 2027.
-
DURAVYU’s two global phase III trials in wet AMD are fully enrolled and on track for data readouts in Q3 2025, with rapid NDA filing and a potential 2027 launch. The program features a novel TKI mechanism, strong safety, robust U.S.-based manufacturing, and a solid cash position supporting operations through key milestones.
-
A bioerodable insert for wet AMD is in two fully enrolled Phase 3 trials, with top-line data expected in mid-2026. The product offers extended dosing intervals and strong safety, with commercial launch targeted for late 2027. Global regulatory and manufacturing preparations are underway.
-
Both phase III trials for DURAVYU™ in wet AMD have completed enrollment with a strong mix of patient types, and top-line data are expected in 2026. The drug's bioerodible technology and robust safety profile support its potential for broad use, with manufacturing and regulatory preparations well underway.
-
Full enrollment in phase III DURAVYU trials for Wet AMD was achieved ahead of schedule, with top-line data expected in mid-2026 and a strong cash position supporting operations into 2027. Revenue declined as the company exited specialty pharma, and commercial launch preparations are underway.
-
DURAVYU, a sustained-release therapy for retinal diseases, is advancing through two pivotal phase III wet AMD trials, with LUGANO fully enrolled and LUCIA nearing full enrollment. Positive phase II DME results support plans for pivotal trials, and a new manufacturing facility is operational to support future commercialization.
-
Enrollment completed for the first phase III trial of DURAVYU in wet AMD, with the second trial nearing completion. DURAVYU offers a novel TKI mechanism, strong safety profile, and potential for extended treatment intervals, with commercial and regulatory preparations advancing.
-
DURAVYU is advancing through two global phase III trials for wet AMD, with strong enrollment and regulatory progress. The therapy offers a novel mechanism, six-month dosing, and is positioned as a maintenance add-on to anti-VEGFs. U.S. commercialization will be solo, with ex-U.S. partnerships planned.
-
DURAVYU phase III trials for Wet AMD are enrolling ahead of expectations, with strong safety and efficacy data supporting confidence in regulatory success. Q1 2025 saw increased revenue from collaborations, higher R&D spend, and a robust cash position to fund operations into 2027.
-
Duravyu, a sustained-release TKI for retinal diseases, is in two rapidly enrolling phase III trials for wet AMD, with strong phase II efficacy and safety data. The product aims to reduce treatment burden, offers potential antifibrotic benefits, and is supported by robust U.S.-based manufacturing.
-
DURAVYU, an erodible ocular drug delivery system, is advancing through two global phase III trials for wet AMD, with rapid enrollment and strong safety and efficacy data. Market potential is significant in both wet AMD and DME, with commercial launch targeted post-2026 and robust cash reserves supporting operations.
-
DURAVYU, a sustained-release tyrosine kinase inhibitor, is advancing through phase III trials for wet AMD and has shown strong safety and efficacy in both wet AMD and DME. The company is well-funded, targeting every six-month dosing, and expects pivotal data in 2026.
-
DURAVYU, a sustained-release therapy for retinal diseases, is advancing rapidly through phase III trials for wet AMD, with strong phase II results in DME and a robust safety profile. The company is well-funded, expects pivotal data in 2026, and targets major market opportunities in both indications.
-
Duravyu, a novel sustained-release therapy for retinal diseases, is advancing rapidly through global Phase III trials, with strong safety and efficacy data in both wet AMD and DME. The company is well-funded, expects regulatory filings in 2026, and is planning global commercialization with potential partners.
-
Six-month phase II data in DME showed DURAVYU achieved non-inferior visual and anatomic outcomes to aflibercept with fewer supplements and a strong safety profile. Plans are in place for a single pivotal phase III trial, leveraging robust funding and manufacturing capacity.
-
Duravyu, a sustained-release insert for retinal diseases, is advancing through two global Phase 3 wet AMD trials and has shown strong interim Phase 2 results in DME, with high supplement-free rates and favorable safety. The company is financially positioned for continued development and is targeting large market opportunities in both wet AMD and DME.
Fiscal Year 2024
-
Advanced DURAVYU into phase III trials for wet AMD, reported strong phase II DME data, and ended 2024 with $371M cash and no debt. Exceeded enrollment targets, transitioned manufacturing, and expect cash runway into 2027.
-
Duravyu's Phase III Wet AMD trials are progressing ahead of schedule, with strong safety and efficacy data supporting its potential for significant market penetration. Recent DME results show rapid, superior vision gains, and a new facility ensures commercial readiness. Financials are strong, and pipeline expansion is underway.
-
DURAVYU has shown strong efficacy and safety in both wet AMD and DME, with pivotal trials underway and a robust cash position supporting future growth. The company is advancing a differentiated long-acting therapy and expanding its pipeline, with key data and regulatory milestones expected over the next 18 months.
-
DURAVYU, a sustained-release TKI, showed strong interim DME data and is advancing in global phase III wet AMD trials, with top-line results expected mid-2026. The product offers six-month maintenance therapy, has robust patent protection, and recent financing extends cash runway into 2027.
-
Duravyu, an erodible sustained-release insert for wet AMD, showed strong phase II results with non-inferior efficacy and excellent safety versus Eylea. Two pivotal phase III trials are launching with rapid enrollment, targeting both naive and previously treated patients, and regulatory alignment is strong.
-
Strong phase II data in wet AMD supports imminent phase III trials, with a focus on sustained-release therapy and broad patient inclusion. Physician feedback is positive, and preparations for large-scale enrollment are nearly complete.
-
Entering phase III trials for DURAVYU in wet AMD, the company has strong phase II data, FDA alignment, and robust site activation. The pipeline includes novel programs, and cash reserves are sufficient through 2026 top-line data.
-
DURAVYU, a sustained-release intravitreal insert for wet AMD and DME, demonstrated non-inferiority to aflibercept and significantly reduced treatment burden in phase II trials, with no serious safety concerns. Two pivotal phase III trials are planned, and top-line DME data is expected in Q1 2025.
-
DURAVYU, a sustained-release vorolanib insert for wet AMD, showed strong 12-month efficacy and safety, reducing treatment burden and maintaining vision stability. Phase III trials are set to enroll both naive and previously treated patients, with regulatory alignment and commercial manufacturing underway.
-
DURAVYU, a sustained-release insert for retinal diseases, showed strong phase 2 results in wet AMD, reducing treatment burden and matching EYLEA in efficacy and safety. Phase 3 trials in wet AMD will start in H2 2024, with robust financials supporting ongoing development.